> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# MPM BioImpact Holds 8.6% Of Corbus — The Adviser Says It Isn't Seeking Control
- URL: https://www.bullished.co/mpm-bioimpact-holds-8-6-of-corbus-the-adviser-says-it-isnt-seeking-control-ed4e06fe/
- Published: 2026-11-13T17:35:55.000Z
- Updated: 2026-11-13T17:35:55.000Z
- Description: Corbus is advancing a late-stage cancer trial alongside an early-stage obesity drug study.
- Author: Matteo Parrino
- Tags: SEC Filings, CRBP, Industry: Healthcare

MPM BioImpact, an investment adviser, reported an [8.6% stake](https://www.sec.gov/Archives/edgar/data/0001687078/000168707826000022/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Corbus Pharmaceuticals](https://www.bullished.co/tag/crbp/), which develops experimental cancer and obesity treatments, in an SEC ownership disclosure filed Friday. The adviser certified that the holding was not intended to change or influence control of the company.

## 1.7 Million Shares, Sole Voting Power

MPM BioImpact's position comprised [1,667,272 shares](https://www.sec.gov/Archives/edgar/data/0001687078/000168707826000022/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) as of September 30, 2026\. The adviser reported sole authority to vote and dispose of those shares.

The passive ownership disclosure places the investment within MPM BioImpact's ordinary business activities. Its certification covers both the purchase and continued holding of the securities.

## Cancer Trial Targets An Approval Path

Corbus began [dosing patients](https://www.globenewswire.com/news-release/2026/11/10/3399418/0/en/corbus-pharmaceuticals-reports-q3-2026-financial-results-and-provides-a-corporate-update.html?ref=bullished.co) in September in TEMPO-1, its late-stage oropharyngeal cancer study, according to the company's corporate update. The FDA cleared the study in July 2026.

The trial compares sutantatug envedotin with treatments selected by investigators for patients whose cancer has previously been treated. Corbus intends to use tumor-response findings to support potential accelerated approval, with overall-survival findings supporting conversion to full approval.

Corbus has no approved products for sale. Its cancer candidate CRB-701 delivers a cell-killing payload by targeting the Nectin-4 protein on cancer cells. Corbus licenses it from CSPC for the United States, Canada, European Union, United Kingdom and Australia.

The company relies on contract manufacturers and licensing partners for drug supply and owns no manufacturing facilities. Research and development spending totaled $70.1 million in 2025.

## Obesity Pill Posts Early Weight Loss

Participants taking [60 mg daily](https://www.globenewswire.com/news-release/2026/11/10/3399418/0/en/corbus-pharmaceuticals-reports-q3-2026-financial-results-and-provides-a-corporate-update.html?ref=bullished.co) of CRB-913 recorded mean weight loss of 5% after 12 weeks in an early-stage study, Corbus reported. The company said weight loss had not reached a plateau.

CRB-913 is an oral obesity treatment that blocks the cannabinoid type-1 receptor. Its early-stage study includes 240 U.S. participants.

Corbus had a market capitalization of $70 million in Friday trading as of 12:34 p.m. ET.

Corbus expects first-quarter 2027 results from testing sutantatug envedotin with Keytruda as an initial treatment for oropharyngeal cancer.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — MPM BioImpact LLC re: Corbus Pharmaceuticals Holdings, Inc. (CRBP)](https://www.sec.gov/Archives/edgar/data/0001687078/000168707826000022/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Corbus Pharmaceuticals Reports Q3 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/10/3399418/0/en/corbus-pharmaceuticals-reports-q3-2026-financial-results-and-provides-a-corporate-update.html?ref=bullished.co) — globenewswire.com

### More on Corbus Pharmaceuticals

- [Corbus Expects $115.3 Million To Fund Operations Into 2028 As Cancer Trials Advance](https://www.bullished.co/corbus-expects-115-3-million-to-fund-operations-into-2028-as-cancer-trials-advance-555da1ca/)
- [Corbus Deck Marks First TEMPO-1 Patient Dosed, Targets 2H 2028 Filing For CRB-701](https://www.bullished.co/corbus-deck-marks-first-tempo-1-patient-dosed-targets-2h-2028-filing-for-crb-701-6838de2f/)

[All Corbus Pharmaceuticals (CRBP) coverage →](https://www.bullished.co/tag/crbp/)